Home  »  Business   »  Before Buying Kronos Bio Inc. (NASDAQ: KRON) Stock...

Before Buying Kronos Bio Inc. (NASDAQ: KRON) Stock, Read This First

Kronos Bio Inc. (NASDAQ:KRON) shares, rose in value on Friday, 05/13/22, with the stock price down by -2.25% to the previous day’s close as strong demand from buyers drove the stock to $3.91.

Actively observing the price movement in the last trading, the stock closed the session at $4.00, falling within a range of $3.78 and $4.19. Referring to stock’s 52-week performance, its high was $28.42, and the low was $3.87. On the whole, KRON has fluctuated by -38.91% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of Kronos Bio Inc. currently standing at about $238.51 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 21, 2022 – Mar 25, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$1.1, which is expected to increase to -$0.65 for fiscal year -$2.72 and then to about -$3.08 by fiscal year 2022. Data indicates that the EPS growth is expected to be 49.90% in 2022, while the next year’s EPS growth is forecast to be -13.20%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that KRON’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of KRON currently trading nearly -21.25% and -37.90% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 27.40, while the 7-day volatility ratio is showing 9.84% which for the 30-day chart, stands at 8.94%. Furthermore, Kronos Bio Inc. (KRON)’s average true range (ATR) is 0.45.

Data on historical trading for Kronos Bio Inc. (NASDAQ:KRON) indicates that the trading volumes over the past 3 months, they’ve averaged 328.10K. According to company’s latest data on outstanding shares, there are 55.84 million shares outstanding.

Nearly 2.70% of Kronos Bio Inc.’s shares belong to company insiders and institutional investors own 68.50% of the company’s shares. The stock has fallen by -71.23% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the KRON stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam